Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III TrialShukui Qin, Chunyi Hao, Xin Wang et al.|Journal of Clinical Oncology|2022Cited by 191
Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.Shukui Qin, Chunyi Hao, Zhendong Chen et al.|Journal of Clinical Oncology|2022Cited by 111
Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.Feng Bi, Feng Chen, Shukui Qin et al.|Journal of Clinical Oncology|2020Cited by 39
Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and/or immunotherapy: An open-label, single-arm, phase 1/2 dose-escalation and expansion study.Zhenggang Ren, Stephen L. Chan, Yabing Guo et al.|Journal of Clinical Oncology|2023Cited by 25
SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancerJin Li, Shukui Qin, Yuxian Bai et al.|Cancer Immunology Immunotherapy|2024Cited by 15